Filtered By:
October 23, 2024
Alzheimer's
Research
Neurodegenerative disorders, such as Alzheimer's disease (AD) and Lewy Body disease, often present increasing co-pathologies with time and disease progression. In AD patients, amyloid plaques, tau tangles, and alpha-synuclein aggregates (Lewy bodies, LBs) are commonly found in brain tissue at autopsy, suggesting overlap - or "cross-talk' - between and among these pathogenic entities that ultimately lead to synaptic death and cognitive impairment. Dr Tosun and colleagues recently tested cerebrospinal fluid (CSF) samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort and found that 22% contained pathogenic forms of LBs. The prevalence of LBs was found to increase with disease stage and age, and was associated with greater cognitive decline and earlier symptom onset. LB prevalence and its associations with AD biomarkers have been published in two separate articles this year, one with cross-sectional data and the other with longitudinal data from the ADNI.
November 16, 2023
Alzheimer's
Research
This week, Nature News highlighted AI approaches that work to better identify Alzheimer's Disease. One of these was from our article titled, "Identifying Individuals with Non-Alzheimer's Disease Co-Pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease", wherein researchers developed a tool to ascribe the presence of non-Alzheimer's neuropathologies that contribute to the progression of this neurodegenerative disease.
October 6, 2023
Alzheimer's
PET
Research
In a significant collaborative effort between researchers and Siemens, the Medical Imaging Informatics and Artificial Intelligence center has unveiled a novel approach to understanding Alzheimer's disease (AD) progression. Their recently published paper titled "Profiling and Predicting Distinct Tau Progression Patterns: An Unsupervised Data-Driven Approach to Flortaucipir Positron Emission Tomography" sheds light on a pioneering technique that could reshape AD clinical trials and patient care.
March 6, 2023
Alzheimer's
Clinical diagnosis of Alzheimer’s disease (AD) is through a comprehensive cognitive testing, assessment of medical and family history, and symptom tracking. The true diagnosis of Alzheimer’s disease is actually done at autopsy.
March 1, 2023
Alzheimer's
Early detection of slow-progressing, long-term diseases such as Alzheimer’s (AD) is preferred among all involved – patients, caregivers, clinicians, and physicians alike.
January 17, 2022
Alzheimer's
PET
Connected in vivo tau positron emission topography (PET) Magnetic Resonance Imaging (MRI) with a deep learning process that can accurately measure early Alzheimer’s Disease pathology